827 related articles for article (PubMed ID: 21102634)
1. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
Lens SM; Voest EE; Medema RH
Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?
Archambault V; Carmena M
Cell Cycle; 2012 Apr; 11(8):1490-5. PubMed ID: 22433949
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
Christoph DC; Schuler M
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
[TBL] [Abstract][Full Text] [Related]
5. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
6. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
7. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
8. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
Warner SL; Stephens BJ; Von Hoff DD
Curr Oncol Rep; 2008 Mar; 10(2):122-9. PubMed ID: 18377825
[TBL] [Abstract][Full Text] [Related]
9. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
Li JJ; Li SA
Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
Luo J; Liu X
Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of myosin II-interacting guanine nucleotide exchange factor (MyoGEF) at threonine 544 by aurora B kinase promotes the binding of polo-like kinase 1 to MyoGEF.
Wu D; Asiedu M; Matsumura F; Wei Q
J Biol Chem; 2014 Mar; 289(10):7142-7150. PubMed ID: 24482237
[TBL] [Abstract][Full Text] [Related]
12. Aurora B: a new prognostic marker and therapeutic target in cancer.
Portella G; Passaro C; Chieffi P
Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
14. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
Diallo A; Prigent C
Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.
Macůrek L; Lindqvist A; Lim D; Lampson MA; Klompmaker R; Freire R; Clouin C; Taylor SS; Yaffe MB; Medema RH
Nature; 2008 Sep; 455(7209):119-23. PubMed ID: 18615013
[TBL] [Abstract][Full Text] [Related]
16. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
17. Aurora-A and hBora join the game of Polo.
Macurek L; Lindqvist A; Medema RH
Cancer Res; 2009 Jun; 69(11):4555-8. PubMed ID: 19487276
[TBL] [Abstract][Full Text] [Related]
18. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.
Pérez Fidalgo JA; Roda D; Roselló S; Rodríguez-Braun E; Cervantes A
Clin Transl Oncol; 2009 Dec; 11(12):787-98. PubMed ID: 20045785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
